ID   EEB
AC   CVCL_8685
DR   CLO; CLO_0051023
DR   BioSample; SAMN03471963
DR   JCRB; JCRB1846
DR   RCB; RCB2345
DR   Wikidata; Q54832036
RX   PubMed=16332389;
CC   Population: Japanese.
CC   Doubling time: 38 hours (PubMed=16332389).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): JCRB=JCRB1846; RCB=RCB2345
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 9,12
ST   D16S539: 10,12
ST   D5S818: 11
ST   D7S820: 10
ST   TH01: 7
ST   TPOX: 8,9
ST   vWA: 16,17 (RCB=RCB2345)
ST   vWA: 17 (JCRB=JCRB1846)
DI   NCIt; C8923; Acute erythroid leukemia
DI   ORDO; Orphanet_318; Acute erythroid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   49Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 15
//
RX   PubMed=16332389; DOI=10.1016/j.leukres.2005.10.021;
RA   Kawano-Yamamoto C., Muroi K., Nagatsuka Y., Higuchi M., Kikuchi S.,
RA   Nagai T., Hakomori S.-i., Ozawa K.;
RT   "Establishment and characterization of a new erythroblastic leukemia
RT   cell line, EEB: phosphatidylglucoside-mediated erythroid
RT   differentiation and apoptosis.";
RL   Leuk. Res. 30:829-839(2006).
//